CRNX - Company ID 0001658247
Crinetics Pharmaceuticals, Inc. trades as CRNX and has a market capitalization of $8.81 B, making it the #1037 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $7.70M, up 640.7% from the prior year and net income of -$465.30M. This page tracks Crinetics Pharmaceuticals, Inc. through 670 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Crinetics Pharmaceuticals, Inc.'s revenue grew from $589.00K to $7.70M, a compound annual growth rate of 33.1%. Net profit margin compressed from -1021.9% to -6046.0% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider sale notice | 144 | 2026-05-04 |
| SCHEDULE 13G | - | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
Crinetics | Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
Crinetics | Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link ( HERE ) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.
Crinetics | Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Crinetics | Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
The largest companies sharing Crinetics Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Crinetics Pharmaceuticals, Inc. (CRNX) has a market capitalization of $8.81 B as of 2026-07-09, ranking #1037 among US-listed companies.
Crinetics Pharmaceuticals, Inc. reported revenue of $7.70M for fiscal year 2025, an increase of 640.7% year over year.
In its latest fiscal year Crinetics Pharmaceuticals, Inc. reported a net loss of $465.30M.